Across the federal government, agencies are working to address the intersection between mpox and HIV. Find federal resources on mpox and HIV targeting consumers, clinicians, grantees, and other audiences.

Centers for Disease Control and Prevention (CDC)

Resources for Consumers and Community Partners

• CDC.gov/poxvirus/mpox—This is CDC’s main mpox page, providing the latest public health information on mpox symptoms, vaccination, treatment, and prevention for the general public and health care professionals.
• CDC Mpox Digital Resources—This page provides consumer fact sheets, flyers, posters, and other resources with the latest information on how to prevent and treat mpox.
• Get Healthy and Ready for the Year Ahead—This consumer fact sheet discusses steps to stay healthy before, during, and after summer LGBTQIA+ celebrations, including learning about mpox and getting a two-dose mpox vaccine, if recommended for you.
• Let’s Talk About Mpox VideosExit Disclaimer—CDC and KFF’s We Are Greater Than initiative launched this series of direct, plain language mpox FAQ videos featuring Demetre Daskalakis, MD, MPH, Acting Director of CDC’s National Center for Immunization and Respiratory Diseases discussing the importance of getting vaccinated, common mpox symptoms, testing, treatment options, and more.
• Mpox and Spring and Summer Events—This web page provides information and resources for people attending LGBTQIA+ spring and summer events, clinicians, and event organizers.

Resources for Health Departments, Healthcare Providers, and Other Health Professionals

• Information for Health Departments—This CDC page provides information on case definitions, case reporting, and a vaccine equity pilot program.
• Information for Healthcare Providers—This CDC page provides links to information on caring for patients, vaccination, special population considerations, specimen collection, and more.
• Information for Laboratory Personnel—This CDC provides information on laboratory procedures and biosafety and how to report test results.
• Information for Veterinarians—This CDC page provides information on animals with suspected mpox.

Select Articles and Reports

• CDC Director Adopts Recommendation of Routine Use of Mpox Vaccine to Protect Those at Risk— On October 25, 2023, CDC’s Advisory Committee for Immunization Practices (ACIP) unanimously recommended broader and more routine use of the mpox vaccine to prevent the disease in people known to be at risk for mpox. The Committee’s recommendation was adopted by the CDC Director and was made official.
• Characteristics of JYNNEOS Vaccine Recipients Before and During a Large Multiday LGBTQIA+ Festival—This report describes how mpox vaccine equity can be improved and health disparities reduced using community engagement activities primarily for racial and ethnic minorities. The community events described in the report were conducted during the 2022 Southern Decadence festival in Louisiana.  Between August 9 and September 4, 6,854 vaccine doses were administered.
• Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023—This report shows that nearly all the 38 individuals who died from mpox-associated conditions between May 2022 and March 2023 were immunocompromised because of HIV. Of the 24 individuals with HIV for whom complete data were available, all had advanced HIV (CD4 counts <50).
• Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection — New York, 2022 —This report shows that a comparison of men with mpox in New York to control patients found adjusted combined 1-dose or 2-dose vaccine effectiveness (VE) of 75.7%, with higher 2-dose VE of >88%.
• Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022 – March 31, 2023—This report shows that adjusted VE was found to be 75% for 1 dose and 86% for 2 doses of JYNNEOS vaccine, regardless of route of administration or immunocompromise status.
• Lessons from the Mpox Response—This January 8, 2024, JAMA Viewpoint discusses key lessons from the nation’s mpox response that can help better manage infectious disease outbreaks in the future.
• Potential Risk for New Mpox Cases—This May 15, 2023, Health Alert Network (HAN) Health Update reports that CDC and local partners are investigating a cluster of mpox cases in the Chicago area. Its purpose is to inform clinicians and public health agencies about the potential for new clusters or outbreaks of mpox cases and to provide resources on clinical evaluation, treatment, vaccination, and testing.
• Racial and Ethnic Disparities in Mpox Cases and Vaccination Among Adult Males— United States, May–December 2022—This report describes racial and ethnic disparities in mpox incidence and vaccination.
• Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons-43 U.S. Jurisdictions, July 31-October 1, 2022—This report presents data showing that for every 1 illness among people who were fully vaccinated with 2 doses, there were 10 illnesses among people who were unvaccinated. People eligible for mpox vaccination should get vaccinated as soon as possible.
• Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox—This report provides demographic characteristics of the 931,155 JYNNEOS vaccine doses administered in the U.S. through October 10, 2022.  The data shows progress has been made in increasing mpox vaccination among people from racial and ethnic minority groups.
• Severe Monkeypox in Hospitalized Patients – U.S. 2022—This report describes severe manifestations of mpox infection observed by CDC between August and October 2022 among 57 hospitalized patients in the U.S., many of whom are immunocompromised persons, including people with HIV who are not in HIV care.
• The CDC Domestic Mpox Response — United States, 2022-2023—This article in the May 18, 2023, Morbidity and Mortality Weekly Report (MMWR) reviews lessons learned to improve response and future readiness and previews continued mpox response and prevention activities as local viral transmission continues in multiple U.S. jurisdictions.
• View All MMWR Reports: Mpox

Health Resources and Services Administration (HRSA)

• Mpox Information—From HRSA’s HIV/AIDS Bureau, this page offers links to current mpox resources specifically for Ryan White HIV/AIDS Program recipients, subrecipients, and stakeholders.

National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

• Monkeypox Treatment Trial Begins in the Democratic Republic of Congo—This October 12, 2022, NIAID news release announces the launch of a clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX.
• NIAID Study Describes Immune Response to Mpox in Woman Living with HIV—This May 11, 2023, NIAID Now blog post discusses how NIAID scientists recently described the clinical and immunological features of a woman living with HIV who acquired mpox while participating in a long-term NIAID study at the NIH Clinical Center. They reported these findings in the Journal of Infectious Diseases.
• NIH Scientists Develop Mouse Model to Study Mpox Virulence—This February 14, 2023, NIAID news release discusses how NIAID scientists have removed a major roadblock to better understanding of mpox by developing a mouse model of the disease and using it to demonstrate clear differences in virulence among the major genetic groups (clades) of mpox virus (MPXV). 
• The STOMP Trial Evaluates an Antiviral for Mpox—This October 10, 2023, NIAID Now blog post discusses the STOMP TrialExit Disclaimer, a trial evaluating the efficacy of the antiviral drug tecovirimat, also known as TPOXX, for the treatment of mpox and is still enrolling participants. The STOMP trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and led by the NIAID-funded AIDS Clinical Trials GroupExit Disclaimer.
  • Beyond STOMP, NIAID is co-sponsoring the PALM007 trial of tecovirimat as treatment for clade I mpox in the Democratic Republic of the Congo (DRC) with the DRC’s National Institute of Biomedical Research. In addition, NIAID is sponsoring an immunogenicity study of the JYNNEOS preventive vaccine, which has completed enrollment and is expected to report initial results in 2024.
• U.S. Clinical Trial Evaluating Antiviral for Monkeypox Begins—This September 9, 2022, NIAID news release announces that the Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the U.S.

Substance Abuse and Mental Health Services Administration (SAMHSA)

• Dear Colleague Letter: Use of Grant Resources for Monkeypox-related Activities—This letter to the agency’s HIV grantees and others clarifies that grantees may use SAMHSA grant resources, including funds or staff, for mpox-related activities conducted in conjunction with SAMHSA-supported activities.
• Feeling Stressed or Anxious About the Monkeypox Outbreak?—This blog post provides tips to reduce stress and anxiety for those worried about mpox.

U.S. Department of Housing and Urban Development (HUD)

• Health Crisis Response Tools and ResourcesExit Disclaimer—This page provides links to mpox resources for HUD-funded homeless service providers and community partners.

U.S. Department of Health and Human Services (HHS)

• Fact Sheet: HHS Provides Resources on Ways Communities Can Stay Protected from Mpox in Advance of Summer Months—This May 2023 fact sheet presents important information and resources to assist communities in helping individuals stay healthy and prevent mpox during the summer months.
• Statement From HHS Secretary Becerra on Mpox—In this December 2, 2022, statement, Secretary Becarra notes that HHS will continue to monitor the case trends closely and encourage all at-risk individuals to get a free mpox vaccine.